XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Summary of the Option Unit Activity (Details)
 9 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Weighted Average Remaining Contractual Term, Grants Vested 1 year 4 months 24 days
2021 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 4,311,662
Number of units, granted | shares 384,994
Number of grants, forfeited | shares (87,038)
Number of units, grant outstanding ending balance | shares 4,609,618
Number of grants, vested | shares 1,548,685
Number of grants, unvested | shares 3,060,933
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 15.24
Weighted average exercise price, grants issued | $ / shares 11.96
Weighted average exercise price, forefeited | $ / shares 15.54
Weighted average exercise price, grant outstanding ending balance | $ / shares 13.57
Weighted average exercise price, grants vested | $ / shares 13.64
Weighted average exercise price, grants unvested | $ / shares $ 13.53
Weighted Average Remaining Contractual Term, Grants Outstanding 8 years
Weighted Average Remaining Contractual Term, Grants Vested 7 years 10 months 24 days
Aggregate Intrinsic Value, grants outstanding | $ $ 2,100,000
Aggregate Intrinsic Value, grants vested | $ $ 500
First Advantage Corporation [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 2,843,342
Number of grants, exercised | shares (357,772)
Number of grants, forfeited | shares (533,715)
Number of units, grant outstanding ending balance | shares 1,951,855
Number of grants, vested | shares 539,767
Number of grants, unvested | shares 1,412,088
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 6.66
Weighted average exercise price, grants issued | $ / shares 6.13
Weighted average exercise price, forefeited | $ / shares 6.68
Weighted average exercise price, grant outstanding ending balance | $ / shares 5.15
Weighted average exercise price, grants vested | $ / shares 5.12
Weighted average exercise price, grants unvested | $ / shares $ 5.16
Weighted Average Remaining Contractual Term, Grants Outstanding 6 years 4 months 24 days
Weighted Average Remaining Contractual Term, Grants Vested 6 years 2 months 12 days
Aggregate Intrinsic Value, grants outstanding | $ $ 16,900,000
Aggregate Intrinsic Value, grants vested | $ $ 4,700,000